San Diego-based biotechnology company Samumed has recently announced that it will be moving to phase 3 clinical trials of its drug lorecivivint (SM04690) for the treatment of knee osteoarthritis. What is osteoarthritis? Osteoarthritis is the most common form of arthritis in the knee and a leading cause of adult disability, particularly among older people. This…

Researchers from the University of Luxembourg and the German Cancer Research Center have rejuvenated stem cells in the brains of old mice. The rejuvenated stem cells appear to improve regeneration in areas of damaged or diseased brain tissue. A new way to model stem cells A new study that was published in the journal Cell…

Today, we were pleased to hear that Samumed, a San Diego-based biotech company working on regenerative medicine, has just raised $438 million towards developing anti-aging therapies. SAN DIEGO – August 6, 2018 – Samumed, LLC, announced today that it has closed its A-6 Round of equity issuance with $438 million, bringing its total equity raised…

© 2018 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

       Powered by MMD